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ABSTRACT
Adults with childhood onset GH deficiency (GHD) have reduced
bone mass, increased fat mass, and disorders of lipid metabolism. The
aim of the present study was to evaluate bone mineral density (BMD),
bone metabolism, body composition, and lipid metabolism in GHD
children before and during 2–3 yr of GH treatment (GHRx). Forty
children with GHD, mean age 7.9 yr, participated in the study of bone
metabolism and body composition; and an additional group of 17 GHD
children, in the study of lipid metabolism. Lumbar spine BMD, total
body BMD, and body composition were measured with dual-energy
x-ray absorptiometry. Volumetric BMD (bone mineral apparent den-
sity, BMAD) was calculated to correct for bone size. BMD, BMAD, lean
tissue mass, bone mineral content, fat mass, and percentage body fat
were expressed as SD scores (SDS), in comparison with normative data
of the same population. Lumbar spine BMD and BMAD and total body
BMD were all decreased at baseline. All BMD variables increased
significantly during GHRx, lumbar spine BMD SDS, already after 6
months of treatment. Lean tissue mass SDS increased continuously.
Bone mineral content SDS started to increase after 6 months GHRx.
Fat mass SDS decreased during the first 6 months of GHRx and
remained stable thereafter. Biochemical parameters of bone forma-
tion and bone resorption did not differ from normal at baseline and
increased during the first 6 months of GHRx. Serum 1,25 dihydroxyvi-
tamin D increased continuously during GHRx, whereas PTH and
serum calcium remained stable. Lipid profile was normal at baseline.
Atherogenic index had decreased and apolipoprotein A1 (Apo-A1) had
increased after 3 yr of treatment.
In conclusion, children with GHD have decreased bone mass. BMD,
together with height and lean tissue mass, increased during GHRx.
GHRx had a beneficial effect on lipid metabolism. (J Clin Endocrinol
Metab 82: 2423–2428, 1997)
GH IS ESSENTIAL for normal growth during childhoodand adolescence and influences bone mineralization
and body composition in children and adults. In adults, GH
is known to affect lipid metabolism. GH deficiency (GHD) of
childhood onset in adults and GHD in children are associated
with reduced bone mineral density (BMD) and lean tissue
mass and increased fat mass (1–6). Studies in adults showed
that these abnormalities change to normal after long-term
treatment with human GH (1, 7). Few reports showed that
BMD improved in GHD children during GH therapy (5, 6).
Bone mass accumulation during childhood determines the
peak bone mass, which is a major determinant of osteopo-
rosis later in life. Adults with GHD have an increased risk of
cardiovascular disease because of disorders in lipid metab-
olism, which improve during GH therapy (GHRx) (8, 9).
Reduction in triglycerides (TG) and low-density lipoprotein
cholesterol (LDL) and increase of high-density lipoprotein
cholesterol (HDL) have been observed in adults with GHD
during therapy (8–10). Reports of lipid metabolism during
GHRx in children with GHD are contradictory (11–13).
In the present study, lumbar spine and total body BMD,
lumbar spine BMD corrected for estimated bone volume,
bone metabolism, body composition, and lipid metabolism




Forty children (24 boys and 16 girls) participated in the study. The
mean age at the start of treatment was 7.9 yr (range 0.4–16.9). In 2
children, younger than 4 yr, no BMD measurements were performed. In
these young children, it is difficult to lie still to perform the measure-
ment. One of them became 4 yr old after 2 yr of treatment, and then BMD
measurements were performed.
All patients had decreased height velocity. The children had height
sd scores (SDS) below 2, compared with Dutch reference values (14),
except three patients. These children had a craniopharyngioma, low
height velocity, and height SDS below 21.
Eighteen children (14 boys and 4 girls, mean age 8.7 yr) had classic
GHD, defined as 2 different GH provocation test peaks less than 5 mg/L
and insulin-like growth factor (IGF)-1 and IGF-binding protein 3 (IGF-
BP3) below the mean of age- and sex-matched healthy controls (15). The
other 22 patients (10 boys and 12 girls, mean age 7.4 yr) were categorized
as nonclassic GHD. The diagnosis of 16 children was partial GHD,
defined as GH provocation peaks between 5–10 mg/L and IGF-1 and
IGF-BP3 below the mean, or GH provocation peaks between 10–15 mg/L
and IGF1 and IGF-BP3 below 2 sd of normal. Five children formed a
special group: 2 of them had GH provocation peaks more than 15 mg/L
but IGF-1 and IGF-BP3 below 2 sd, and 2 had GH peaks between 10–15
mg/L and IGF-1 and IGF-BP3 that were 1.5 sd below normal. One girl
had GH peaks between 10–15 mg/L but normal IGF-1. These 5 children
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had high IGF-1 response during a test after stimulation with GH. One
girl with intrauterine growth retardation, without catch-up growth, had
normal GH-peaks and IGF-1 of 21 sd and a very low height SDS (24.6
sd). Sixteen children had GHD of unknown origin. Eighteen had GHD
of known origin: 8 had a malformation in the central nervous system,
2 had a syndrome with GHD (1 Prader-Willi and 1 Robinow), 7 had an
intracerebral tumor (5 craniopharyngioma, 1 germinoma, and 1 astro-
cytoma), and 1 boy had received radiation therapy for a rhabdomyo-
sarcoma of his left ear. Two children had Noonan syndrome, and 4 were
born after intrauterine growth retardation.
Eight children had multiple pituitary hormone deficiencies and re-
ceived hormonal replacement therapy. All patients had normal thyroid
function before and during treatment.
Thirty-two patients were prepubertal (14 with classic and 18 with non-
classic GHD), 5 had Tanner stage 2 (2 with classic and 3 with nonclassic
GHD), 2 had Tanner stage 3 (1 with classic and 1 with nonclassic GHD), and
1 had Tanner stage 4 (with classic GHD) (16). Three children (1 with classic
and 2 with nonclassic GHD) entered puberty during the study period.
In the above mentioned children and 17 other children (10 boys and
7 girls, mean age 7.9 yr, sd 3.1), lipid metabolism was measured at
baseline and during GH therapy. Of these 17 children, 6 patients had
classic and 11 had nonclassic GHD. Eight had idiopathic GHD and 9 had
GHD of known origin: 4 had a malformation in the central nervous
system, 1 had an optic glioma, 1 had a pituitary microadenoma, 2 had
hydrocephalus, and 1 had neurofibromatosis. The child with the optic
glioma had multiple pituitary deficiencies. Fifteen were prepubertal, 1
had Tanner stage 1, and 1 had Tanner stage 2. Lipid profile was eval-
uated at baseline in 55 children; after 1 yr, in 45 children; after 2 yr, in
33 children; and after 3 yr therapy, in 16 children.
All patients were treated with daily sc injections of biosynthetic
human GH (2 IU/m2 body surface). The five children of the group of the
IGF-1 response test received 3 IU/m2.
Informed consent was obtained from the parents of the patients.
Methods
Anthropometry, BMD and body composition measurements, and
assessment of biochemical bone parameters were performed at baseline
and 6 months, 1 yr, and 2 yr after onset of GHRx. BMD and body
composition measurements at 6 months missed in one patient. Height
was measured with a Harpenden stadiometer. Height was compared
with age- and sex-matched reference values (14) and expressed as (SDS).
Body mass index was calculated as weight/(height)2 (kg/m2) and com-
pared with age- and sex-matched reference values (17) and expressed as
SDS.
BMD (g/cm2) of the lumbar spine and total body was measured by
dual-energy x-ray absorptiometry (Lunar, DPXL/PED, Lunar Radiation
Corporation, Madison, WI). The coefficient of variation has been re-
ported as 1.04% for lumbar spine and 0.64% for total body (18). The
coefficient of variation (sd) for lumbar spine was 1.1 (0.2 %) in our
setting. The width of the vertebrae, measured by DXA, was used to
calculate lumbar spine volumetric BMD, bone mineral apparent density
(BMAD), with the model BMAD 5 BMD 3 [4/(p 3 width)] (19). BMD
and BMAD results were compared with our age- and sex-matched Dutch
reference values (n 5 500, 4–20 yr old) (20) and expressed as SDS. With
the total body measurement by DXA, the body composition was mea-
sured as lean tissue mass (g), fat mass (g), and bone mineral content (g).
Total tissue mass is the sum of these three variables. Percentage body
fat is given for total tissue mass. The coefficients of variation have been
reported as 2.2% for fat mass, 1.1% for lean tissue mass, and 0.6% for
bone mineral content (18). Bone mineral content, lean tissue mass, fat
mass, and percentage body fat were compared with our age- and sex-
matched Dutch reference values (4–20 yr old) and expressed as SDS (21).
Bone age was assessed yearly by one investigator (M. Engels), using
an x-ray of the left hand, according to the Tanner-Whitehouse radius-
ulna-short bones method (22).
Blood samples were taken in the morning for the assessment of
calcium, phosphate, alkaline phosphatase, 1,25 dihydroxyvitamin D,
PTH, osteocalcin, the carboxyterminal propeptide of type I collagen
(PICP), cross-linked telopeptide of collagen I (ICTP), and IGF-1. Osteo-
calcin and intact PTH were measured by RIA (Incstar Corporation,
Stillwater, MN); 1,25 dihydroxyvitamin D by RIA by Immuno Diag-
nostic Systems (Boldon, UK). PICP and ICTP was measured with an RIA
kit (Orion Diagnostica, Espoo, Finland) with coefficients of variation of
4–6% and 4–8%, respectively. Our own reference values for osteocalcin,
PICP, and ICTP (respectively n 5 25, n 5 82, and n 5 88) were used for
prepubertal children. Reference values for the older children were de-
rived from other studies that used the same assays (23–25). For mea-
surements of IGF-1 (nmol/L), kits from Med-Genix Diagnostics, Fleurus,
Belgium, were used. IGF-1 sex- and age-matched reference values were
based on 600 samples of a healthy Dutch population (15). In the first
morning, void of urine, the ratio of hydroxyproline and creatinine
(OHP/creat) and the ratio of calcium and creatinine (CA/creat) were
evaluated.
Fasting blood samples were obtained yearly for the assessment of TG,
total cholesterol (TC), HDL, LDL, very low-density lipoprotein choles-
terol (VLDL), free fatty acids (FFA), Apo-A1, and apolipoprotein B
(Apo-B). Atherogenic index was calculated as the ratio of TC to HDL.
TC, TG, Apo-A1, and Apo-B were measured on DuPont de Nemours
Dimension analyzer with reagents as provided by the manufacturer (26).
TC is liberated from all lipoprotein particles by detergents; the esterified
fraction (about 70% of TC) is hydrolyzed by the action of cholesterol
esterase. TC is then oxidized by cholesterol oxidase, which generates 1
mol hydrogen peroxide for each mole of cholesterol. The peroxide gen-
erates a chromophore, which is measured photometrically by a triple-
wavelength endpoint technique. The assay is calibrated by human se-
rum samples with reference method-based set points and is directly
comparable with the standard method of Abell-Kendall (27). TG are
converted to free glycerol by lipase, and the glycerol is oxidized (by
glycerol dehydrogenase) to dihydroxy-acetone under formation of
NADH, which is measured using a kinetic, bichromatic method. Pre-
existing glycerol (usually below 0.1 mmol/L) is included in the result
(28).
HDL is analyzed after Apo-B, containing lipoprotein particles, has
been precipitated from the serum by heparin-MnCl2 solution (29). LDL
is calculated by the following Friedewald formula: LDL 5 TC 2 (HDL
1 VLDL), where VLDL 5 TG and * 5 0.45 mmol/L (30).
Apo-B in the assay reacts with polyclonal antibodies against human
Apo-B to form an immunoprecipitate; the reaction is enhanced by add-
ing polyethyleneglycol. The endpoint turbidity is measured by pho-
tometry in a bichromatic procedure (31). Apo-A1 is measured with
polyclonal antibodies against human Apo-A1 (31). This reaction also is
accelerated with polyethyleneglycol. FFA are measured by specific en-
zymatic esterification to Acyl-CoA and a follow-up reaction with acyl-
CoA-oxidase to generate hydrogen peroxide. This hydrogen peroxide is
then measured after color formation with a chromogen (32). Ascorbate
oxidase eliminates vitamin C interference. Dutch age-matched reference
values were used for TC and HDL (33). For the other lipids our own
reference values of 59 healthy children between 2–10 yr and available
reference data (34) were used.
Statistical analysis
One-sample t tests were performed to compare the mean SDS values
with normal. Two-sample t tests were used to compare variables with
a normal distribution between two groups. We tested if the average
within patient change differed from zero with one-sample t test. Pearson
correlation coefficient was calculated to test the association between two
variables with a normal distribution. Spearman’s rank correlation co-
efficient was used, in case of a nonnormal distribution.
Results
Table 1 shows the results of lumbar spine BMD and BMAD
SDS, total body BMD SDS, height SDS, body mass index SDS,
and body composition variables at baseline and during
GHRx. At baseline, lumbar spine BMD and BMAD SDS and
total body BMD SDS were significantly lower than normal
(P , 0.001 for lumbar spine and total body BMD SDS and P ,
0.02 for BMAD SDS). Lumbar spine BMD and BMAD SDS
and total body BMD SDS were below 22 in 11, 3, and 5
patients, respectively. The results of boys did not differ sig-
nificantly from these of girls. Lumbar spine BMD SDS in-
creased already after 6 months GHRx, lumbar spine BMAD
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SDS after 2 yr GHRx (Table 1). Total body BMD SDS de-
creased initially after 6 months GHRx and increased there-
after (Table 1). The observed changes remained if pubertal
children were excluded. Mean lumbar spine and total body
BMD SDS were still significantly lower than zero after 2 yr
GHRx (P , 0.01 for lumbar spine and P , 0.02 for total body);
mean spine BMAD SDS did not differ significantly from zero.
None of the patients had lumbar spine BMD or BMAD SDS
below 22 after 2 yr of treatment. Total body BMD SDS of 4
patients was below 22 at that time, 3 of them also had a low
value at baseline. At baseline mean bone mineral content and
lean tissue mass SDS were decreased (P , 0.001) and per-
centage body fat increased (P , 0.02). Bone mineral content
SDS started to increase after 6 months GHRx. Lean tissue
mass SDS and height SDS increased continuously during
GHRx. Fat mass SDS and percentage body fat SDS decreased
after 6 months GHRx and remained stable thereafter. After
2 yr GHRx mean bone mineral content and lean tissue mass
SDS were still significantly lower than normal (both P ,
0.001); mean fat mass SDS and percentage body fat SDS did
not differ significantly from normal. The BMD variables,
bone mineral content SDS, and lean tissue mass SDS did not
differ significantly between patients with classic GHD and
those with nonclassic GHD. Fat mass and percentage fat SDS
were significantly higher in patients with classic GHD, com-
pared with the other patients (both P , 0.001). The changes
in lumbar spine BMD SDS, BMAD SDS, total body BMD SDS,
and body composition variables during GHRx were not sig-
nificantly different between the classic and nonclassic GHD
patients.
When BMD SDS was calculated for bone age (SDSBA),
mean lumbar spine BMD SDSBA at baseline was significantly
decreased (mean 20.88, sd 1.11, P , 0.001). Mean lumbar
spine BMAD SDSBA and total body BMD SDSBA did not differ
from normal. Because bone age was below 4 yr in 12 children,
no SDSBA could be calculated, because we had no reference
values of that age. During GH therapy, lumbar spine BMD
SDSBA increased significantly; after 1 yr, the mean increase
was 0.34 (sd 0.12, P , 0.01); from 1 to 2 yr, 0.30 (sd 0.42, P ,
0.01). After 2 yr GHRx, mean lumbar spine SDSBA was 20.54
(sd 0.79), significantly lower than zero (P , 0.02). Total body
BMD SDSBA decreased after 1 yr (mean 20.45 (sd 0.70), P ,
0.01) and increased during the 2nd year (mean 0.41 (sd 0.70),
P , 0.05). BMAD SDSBA did not change during the 1st year
and increased during the 2nd year (mean 0.22 (sd 0.35), P ,
0.02).
Table 2 shows the biochemical results at baseline and
during GHRx. Mean osteocalcin, PICP, and ICTP did not
differ from normal at baseline. After 6 months GHRx, os-
teocalcin, PICP, ICTP, alkaline phosphatase, 1,25 dihy-
droxyvitamin D, IGF-1, and OHP/creat had increased sig-
nificantly. Osteocalcin and ICTP remained stable thereafter;
PICP, alkaline phosphatase, phosphate, and OHP/creat de-
creased significantly; 1,25 dihydroxyvitamin D and IGF-1
continued to increase. PTH and CA/creat did not change
TABLE 1. Mean (SD) of different variables at baseline and during GHRx
Baseline 6 MonthsGHRx 1 yr GHRx 2 yr GHRx
n 5 38 n 5 37 n 5 33 n 5 33
Lumbar spine BMD SDS 21.62 (1.22) 21.33 (1.17)a 20.98 (1.11)a 20.64 (0.87)a
Lumbar spine BMAD SDS 20.51 (1.21) 20.50 (1.17) 20.37 (1.06) 20.19 (1.00)a
Total body BMD SDS 20.94 (1.20) 21.35 (1.20)b 21.02 (1.2) 20.61 (1.16)b
Bone mineral content SDS 22.29 (1.11) 22.36 (1.56) 21.52 (1.29)a 21.24 (0.99)a
Lean tissue mass SDS 22.72 (0.83) 21.86 (0.87)a 21.53 (0.79)a 21.14 (0.54)a
Fat mass SDS 20.02 (1.76) 20.59 (1.80)c 20.31 (2.00)c 20.59 (1.63)
% Body fat SDS 0.93 (2.11) 20.39 (1.99)a 20.10 (2.04)a 20.45 (1.66)c
Height SDS 22.98 (0.76) 22.32 (0.84)a 21.86 (0.91)a 21.63 (0.80)a
BMI SDS 0.45 (2.40) 0.24 (2.29) 0.39 (2.42) 0.37 (2.02)
The mean within patient change from baseline was tested.
a P , 0.001; b P , 0.02; c P , 0.01 compared to baseline.
TABLE 2. Mean (SD) of biochemical parameters at baseline and during GHRx in GHD children
Baseline 6 MonthsGHRx 1 yr GHRx 2 yr GHRx
n 5 39 n 5 38 n 5 33 n 5 21
Osteocalcin (mg/L) 13.3 (4.7) 20.8 (8.1)a 20.7 (5.5)a 16.7 (4.2)
PICP (mg/L) 372 (240) 582 (262)a 458 (152) 355 (149)
ICTP (mg/L) 12.9 (4.6) 17.4 (5.6)a 18.1 (4.3)a 16.8 (5.6)
Alkaline phosph. (U/L) 174.4 (51.7) 245.7 (82.0)a 255.6 (93.4)a 226.0 (87.9)b
PTH (ng/L) 18.9 (7.4) 21.0 (7.5) 24.4 (9.2) 24.1 (11.3)
1,25 OH vit. D (pmol/L) 96.2 (25.8) 130.0 (49.3)a 141.4 (46.5)a 158.9 (41.1)a
IGF-1 (nmol/L) 17.0 (24.4) 34.7 (25.4)a 41.5 (29.3)a 45.2 (31.1)a
Calcium (mmol/L) 2.45 (0.09) 2.45 (0.09) 2.44 (0.08) 2.44 (0.08)
Phosphate (mmol/L) 1.41 (0.17) 1.70 (0.21)a 1.63 (0.18)a 1.49 (0.15)b
Urine OHP/creat (mg/g) 105 (77) 133 (47)c 151 (55)c 118 (43)
Urine Ca/creat 0.45 (0.46) 0.46 (0.44) 0.32 (0.25) 0.39 (0.34)
Alkaline phosph., alkaline phosphatase; 1,25 OH vit. D, 1,25 dihydroxyvitamin D; The mean within patient change from baseline was tested.
a P , 0.001; b P , 0.02; c P , 0.01 compared to baseline.
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during GHRx. The results were not different when pubertal
children were excluded.
Table 3 shows the results of lipid metabolism at baseline
and during GHRx. At baseline, the mean levels of the lipid
profile were normal. One child had TC above 6 mmol/L, and
three children had TG above 1.7 mmol/L. All patients had
normal TC and TG after 3 yr GHRx. Only Apo-A1 and
atherogenic index changed significantly during GHRx;
Apo-A1 had increased and atherogenic index had decreased
after 3 yr of GHRx.
At baseline, height SDS correlated with lumbar spine BMD
and BMAD SDS (r 5 0.43, P , 0.01; and r 5 0.36, P , 0.05,
respectively) and not with total body BMD SDS. Body mass
index SDS related to all three BMD variables (r 5 0.51, P ,
0.01 for lumbar spine BMD SDS; r 5 0.52, P , 0.001 for
lumbar spine BMAD SDS; and r 5 0.44, P , 0.01 for total
body BMD SDS). Biochemical bone parameters and IGF-1
SDS did not relate to lumbar spine BMD, BMAD SDS, total
body BMD SDS, or height SDS. IGF-1 SDS correlated with
lean tissue mass SDS (r 5 0.35, P , 0.05) and not with bone
mineral content, fat mass, or percentage body fat SDS. Height
SDS correlated with bone mineral content SDS and lean
tissue mass SDS (r 5 0.69, r 5 0.62, respectively; both P ,
0.001). The different lipids did not relate to fat mass or per-
centage body fat SDS or IGF-1 SDS.
The change (D) in height SDS between baseline and 2 yr
GHRx did not relate to D in lumbar spine BMD or BMAD SDS
or total body BMD SDS during the same period. D in height
SDS related to D in bone mineral content SDS (r 5 0.41, P ,
0.02 after 1 yr; and r 5 0.44, P , 0.05 after 2 yr GHRx). Only
after 6 months GHRx, D in 1,25 dihydroxyvitamin D had a
significant correlation with D lumbar spine BMD and BMAD
SDS (r 5 0.34, P , 0.05; and r 5 0.57, P , 0.001, respectively)
and not with D in total body BMD or bone mineral content
SDS. Changes of the other biochemical bone parameters had
no significant relation with D in lumbar spine BMD or BMAD
SDS or total body BMD or bone mineral content SDS. Only
D in ICTP, after 6 months, correlated with D in height SDS
during the same period (r 5 0.48, P , 0.01 for all children;
r 5 0.40, P , 0.05 only for prepubertal children). D in IGF-1
SDS, after 6 months or after 2 yr, did not relate to D height
SDS. D in 1,25 dihydroxyvitamin D between baseline and 2
yr GHRx related to D in IGF-1 SDS (r 5 0.52, P , 0.05). D in
IGF-1 SDS, after 6 months, correlated with D in lean tissue
mass SDS (r 5 0.45, P , 0.02). D in IGF-1 SDS, between
baseline and 2 yr, correlated negatively with D percentage
body fat (r 5 20.54, P , 0.05). D in IGF-1 SDS did not relate
to D in any lipids or atherogenic index. After 2 yr of treat-
ment, IGF-1 SDS related to lean tissue mass SDS (r 5 0.52, P ,
0.05) and not to the BMD variables or bone mineral content
SDS.
Discussion
During GHRx, lumbar spine BMD and BMAD, and total
body BMD, together with height and lean tissue mass, in-
creased significantly in children with GHD. Biochemical pa-
rameters of bone formation and bone resorption increased,
indicating an enhanced bone turnover. GH has both direct
and indirect actions on bone. In animal models, GH stimu-
lates osteoblast number and function and the production of
various bone matrix factors (35). Paracrine activity of osteo-
blasts stimulates osteoclasts. Bone formation is enhanced
preferentially to bone resorption during GH administration
(35). As in other tissues, part of the effects of GH are mediated
through IGF-1. In childhood, GH affects both linear bone
growth and the accumulation of BMD. In GHD children, both
are decreased, as shown by low height SDS and BMD SDS.
Some studies found a decreased osteocalcin and PICP (36, 37)
in GHD children; others did not find a difference with nor-
mals (38, 39). The wide range in normal values may be the
reason that osteocalcin and PICP were in the normal range
in the present study. Osteocalcin and PICP are related to
linear growth velocity (36, 39, 40). Increased values of all
markers are found during periods of high growth velocity,
such as the first years of life and puberty in healthy children
(40). During GHRx, the increase of both formation and re-
sorption markers reflects growth, modeling, and remodeling
of bone tissue. The increased bone turnover resulted in an
improvement of BMD.
GH increases muscle mass, in agreement with our finding
of an increase in lean tissue mass, and strength (35). This may
be associated with increased physical activity, which may
have a positive effect on BMD.
Lumbar spine BMD of adults with GHD decreases initially
after 3–6 months GHRx and starts to increase after more than
1 yr of treatment (1, 7). In the present study, lumbar spine
BMD had increased and total body BMD decreased after 6
months treatment. BMD is an areal density and does not
adjust for bone size completely. Total body bone mineral








n n n n
Total cholesterol (mmol/L) 55 4.41 (0.93) 45 4.30 (1.26) 33 4.17 (0.82) 16 3.96 (0.85) 3.2–6.0
Triglycerides (mmol/L) 55 0.98 (0.44) 45 1.02 (0.41) 33 0.98 (0.34) 16 0.88 (0.23) 0.2–1.7
LDL (mmol/L) 54 2.75 (0.87) 43 2.63 (1.12) 29 2.44 (0.61) 14 2.46 (0.61) 1.3–3.7
HDL (mmol/L) 55 1.21 (0.28) 44 1.17 (0.29) 33 1.26 (0.30) 16 1.27 (0.27) 0.9–1.6
VLDL (mmol/L) 53 0.44 (0.20) 43 0.48 (0.20) 24 0.45 (0.14) 13 0.40 (0.09) 0.1–0.8
Free fatty acids (mmol/L) 50 0.86 (0.47) 45 0.73 (0.32) 31 0.65 (0.25) 15 0.61 (0.23) 0.2–1.3
Apo-A1 (g/L) 54 1.35 (0.20) 44 1.30 (0.18) 30 1.39 (0.22) 16 1.40 (0.16)a 0.8–1.5
Apo-B (g/L) 54 0.85 (0.22) 44 0.83 (0.29) 30 0.83 (0.15) 16 0.76 (0.17) 0.6–1.1
Atherogenic index 55 3.85 (1.25) 44 3.79 (1.53) 33 3.41 (0.76) 16 3.20 (0.72)b
Atherogenic index 5 total cholesterol to HDL ratio. The mean within patient change from baseline was tested.
a P , 0.05; b P , 0.02 compared to baseline.
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content remained stable during the first 6 months, so the
initial decrease in total body BMD reflects a faster rate of
bone expansion than mineral acquisition. Bone turnover in
trabecular bone, present in lumbar spine, is higher than in
cortical bone, 80% of the total skeleton (41). This may explain
why lumbar spine BMD starts to increase earlier than total
body BMD. During GHRx, patients had an increase of height
SDS. After 2 yr of treatment, BMAD (corrected for estimated
bone volume) had increased, as well, so one may conclude
that finally, true bone density improved during GHRx.
The changes in body composition found in the present
study are in agreement with known lipolytic and anabolic
effects of GH. GHRx had a short-term lipolytic effect during
the first 6 months of treatment, while the anabolic effect
continued. Similar results have been reported in other stud-
ies in adults and children with GHD and short stature chil-
dren during GHRx (1, 42–44).
GH administration had a stimulatory effect on serum 1,25
dihydroxyvitamin D, whereas serum calcium and PTH re-
mained unchanged. More studies found an increase in 1,25
dihydroxyvitamin D in adults (2), as well as in children (4).
Renal 1ahydroxylase activity is enhanced through IGF-1 (45),
which agrees with the correlation we observed between D in
IGF-1 SDS and D in 1,25 dihydroxyvitamin D. The synthesis
of osteocalcin is induced by the action of 1,25 dihydroxyvi-
tamin D (46). Administration of 1,25 dihydroxyvitamin D to
GHD children increased serum osteocalcin levels (47). Part of
the stimulatory action on osteoblastic activity of GH might
be mediated by 1,25 dihydroxyvitamin D. This is supported
by our finding of a correlation between the increase of 1,25
dihydroxyvitamin D and the increase in BMD.
In contrast to adults with GHD, the children in the present
study had normal mean values of lipids at baseline. The
difference in lipid profile between GHD adults and children
may reflect the population trend for a rise in cholesterol and
LDL with increasing age (48). Studies in adults reported a
decrease in TC, LDL, and apo B after 2–12 months GH ad-
ministration (8, 9, 49) and an increase of HDL (10). The
reported effects of GHD on serum lipids in children with
GHD are inconsistent between studies. Some studies showed
no changes in TC and HDL during 6–12 months of GHRx
(12), whereas others found a decrease in TC (13) or an in-
crease in HDL (11). In the present study, the atherogenic
index decreased, in agreement with a study of Kohno et al.
(11) in prepubertal boys during 9 months of GH therapy. In
a study evaluating the efficacy of lipid profiles, the athero-
genic index was the most efficient predictor of coronary heart
disease in adults (50). In healthy children, no age-related
change in TC was observed between 5 and 10 yr of age, but
TC decreased between 10 and 16 yr in boys, as well as in girls
(33). Mean HDL decreased slightly in boys and girls until the
age of 17 (33). Therefore, the decrease in atherogenic index
in the present study may be age-related. However, Apo-A1,
the major apolipoprotein of HDL, increased also, so it seems
that GHRx has a beneficial effect on lipid metabolism in
children with GHD.
In conclusion, children with GHD had low BMD. After 2
yr of GHRx, lumbar spine BMD of all patients was within
normal limits. Eighty-one percent of the patients had normal
total body BMD at that time. The positive influence of GH on
BMD might be mediated partly by the increase of 1,25 di-
hydroxyvitamin D. Fat mass decreased and lean tissue mass
increased during treatment. In contrast to adults, children
with GHD had a normal lipid profile. Atherogenic index
improved during GHRx.
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